Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palm tocotrienols (HOV-12020) in CADASIL
NCT04658823Phase 2Completed
- Sponsor
- Hovid Berhad
- Start
- Dec 2020
- Primary completion
- Feb 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) comparing HOV-12020 with Placebo (2 arms). Primary endpoint: Incidence of manifestations related to clinical worsening at 24 months. Started Dec 2020; status: completed.
02
Drugs
tocovid
03
Conditions
cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
Beyond the preview
Go deeper on NCT04658823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04658823.